

conference bridge number is (877) 368-9836 and the participant pass code is 852136. For financial, grants management, or budget assistance, contact: Angie Tuttle, Grants Management Specialist, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341. Telephone: (770) 488-2719. E-mail: AEN4@cdc.gov.

#### VIII. Other Information

This and other CDC funding opportunity announcements can be found on the CDC Web site, Internet address: [www.cdc.gov](http://www.cdc.gov). Click on "Funding" then "Grants and Cooperative Agreements."

Dated: November 2, 2004.

**William P. Nichols,**

*Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention.*

[FR Doc. 04-24809 Filed 11-5-04; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Advisory Committee; Renewals

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the

renewal of certain FDA advisory committees by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the charters of the committees listed in table 1 of this document for an additional 2 years beyond charter expiration date. The new charters will be in effect until the dates of expiration listed in table 1. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Public Law 92-463 (5 U.S.C. app. 2)).

**DATES:** Authority for these committees will expire on the dates indicated in table 1 of this document unless the Commissioner formally determines that renewal is in the public interest.

TABLE 1.

Name of committee	Date of expiration
Anesthetic and Life Support Drugs Advisory Committee .....	May 1, 2006.
Blood Products Advisory Committee .....	May 13, 2006.
Pulmonary-Allergy Drugs Advisory Committee .....	May 30, 2006.
Drug Safety and Risk Management Advisory Committee .....	May 31, 2006.
Science Advisory Board to the National Center for Toxicological Research .....	June 2, 2006.
Peripheral and Central Nervous System Drugs Advisory Committee .....	June 4, 2006.
Psychopharmacologic Drugs Advisory Committee .....	June 4, 2006.
Transmissible Spongiform Encephalopathies Advisory Committee .....	June 9, 2006.
Science Board to the Food and Drug Administration .....	June 26, 2006.
Allergenic Products Advisory Committee .....	July 9, 2006.
Cardiovascular and Renal Drugs Advisory Committee .....	August 27, 2006.
Endocrinologic and Metabolic Drugs Advisory Committee .....	August 27, 2006.
Oncologic Drugs Advisory Committee .....	September 1, 2006.
Anti-Infective Drugs Advisory Committee .....	October 7, 2006.
Dermatologic and Ophthalmic Drugs Advisory Committee .....	October 7, 2006.
Cellular, Tissue, and Gene Therapies Advisory Committee (formerly Biological Response Modifiers Advisory Committee)	October 28, 2006.

#### FOR FURTHER INFORMATION CONTACT:

Linda A. Sherman, Advisory Committee Oversight and Management Staff (HF-4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1220.

Dated: October 29, 2004.

**Sheila Dearybury Walcoff,**

*Associate Commissioner for External Relations.*

[FR Doc. 04-24842 Filed 11-5-04; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Research Resources; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Research Resources Special Emphasis Panel Clinical Research.

*Date:* November 17-18, 2004.

*Time:* November 17, 2004, 8 a.m. to Adjournment.

*Agenda:* To review and evaluate grant applications.

*Place:* Omni Charlottesville Hotel, 235 West Main Street, Charlottesville, VA 22902.

*Contact Person:* Carol Lambert, PhD, Scientific Review Administrator, Office of Review, National Institutes of Health, NCRR, 6701 Democracy Blvd., 1 Democracy Plaza,

Room 1076, MSC 4874, Bethesda, MD 20892, (301) 435-0814, [lambert@mail.nih.gov](mailto:lambert@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.371, Biomedical Technology; 93.389, Research Infrastructure, 93.306, 93.333, National Institutes of Health, HHS.)

Dated: October 28, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04-24795 Filed 11-5-04; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Environmental Health Sciences; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as